Old Web
English
Sign In
Acemap
>
Paper
>
Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-mutated Relapsed Epithelial Ovarian Cancer: a Case Report
Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-mutated Relapsed Epithelial Ovarian Cancer: a Case Report
2021
Bing Qian
Jin Lu
Wenshu Leng
Zhengqing Yan
Shiqing Chen
Huan Yi
Zhi Jiang
Keywords:
epithelial ovarian cancer
FANCA
PARP inhibitor
Germline
Medicine
Cancer research
Text mining
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]